Low-dose aspirin does not seem to improve survival after prostate cancer diagnosis
Low-dose aspirin use does not seem to reduce the overall risk for prostate cancer death at the population level, according to a new study. However, results for extended exposure periods suggest that low-dose aspirin might be inversely associated with prostate cancer mortality after 5 years from cancer diagnosis.
Leave a Reply